# The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies

> **NCT07020260** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Princess Maxima Center for Pediatric Oncology** · enrollment: 18 (estimated)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **OTHER:** CAR T-cell and Cellular Therapies

## Key facts

- **NCT ID:** NCT07020260
- **Lead sponsor:** Princess Maxima Center for Pediatric Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-06-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07020260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07020260, "The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07020260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*